Westview Management dba Westview Investment Advisors Invests $955,000 in TG Therapeutics, Inc. $TGTX
by Sarita Garza · The Markets DailyWestview Management dba Westview Investment Advisors purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) during the 4th quarter, Holdings Channel reports. The fund purchased 32,024 shares of the biopharmaceutical company’s stock, valued at approximately $955,000.
Other hedge funds also recently modified their holdings of the company. Johnson Financial Group Inc. bought a new position in shares of TG Therapeutics during the second quarter worth about $25,000. Danske Bank A S bought a new stake in TG Therapeutics during the third quarter valued at $25,000. Optiver Holding B.V. raised its position in shares of TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 732 shares in the last quarter. Bessemer Group Inc. increased its holdings in TG Therapeutics by 117.1% in the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in TG Therapeutics in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 58.58% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have weighed in on TGTX. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. JPMorgan Chase & Co. decreased their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. Finally, Wall Street Zen downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.
TG Therapeutics Stock Down 0.9%
TG Therapeutics stock opened at $30.08 on Monday. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $46.48. The company has a quick ratio of 3.29, a current ratio of 4.10 and a debt-to-equity ratio of 0.38. The firm has a 50 day moving average price of $29.56 and a 200-day moving average price of $31.52. The company has a market capitalization of $4.80 billion, a P/E ratio of 10.86 and a beta of 1.87.
TG Therapeutics (NASDAQ:TGTX – Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The firm had revenue of $192.57 million during the quarter, compared to analysts’ expectations of $192.15 million. During the same period in the prior year, the business earned $0.15 earnings per share. The business’s quarterly revenue was up 78.0% compared to the same quarter last year. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.
About TG Therapeutics
TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.
In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.
Read More
Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).